Home

Ghiath M. Sukhtian

CIK 1717441 · last filed 2026-08-14

Ghiath M. Sukhtian is a corporate insider who has filed 8 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider bought $5.0M of OTLK on Aug 14, 2026. Across all open-market trades the lifetime net is +$5.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $16.4M across reported positions. 13 SEC filings were submitted jointly with BioLexis Pte Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$16.41M

Companies

3

Total Filings

8

Lifetime Open-Market Net

$5.00M

Filer Profile

Reported Address
7TH CIRCLE, ZAHRAN ST.
ZAHRAN PLAZA BUILDING, 4TH FLOOR
AMMAN, M2 11844
Related Filers
BioLexis Pte Ltd. — 13 joint filings, latest 2020-03-23
GMS Ventures & Investments — 13 joint filings, latest 2026-08-14
Arun Kumar Pillai — 13 joint filings, latest 2020-03-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK Director 24,617,320 $0.67 $16.41M $5.00M 2 2026-08-14
Outlook Therapeutics, Inc. (OTLKW) Delisted Director 14,039,494 $0.03 $421.2K $0 4 2019-12-31
Outlook Therapeutics, Inc. (ONSIW) Delisted Director 6,377,383 — — $0 2 2018-07-20

Recent Filings

8 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 OTLK Buy (P) +5,050,504 $5.00M EDGAR
2025-05-28 OTLK Grant (A) +8,571,428 $12.00M EDGAR
2019-12-31 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2019-09-30 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) — $0 EDGAR
2019-06-19 Outlook Therapeutics, Inc. (OTLKW) Delisted Exer (M) +6,545,454 $0 EDGAR
2019-04-16 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) +10,909,092 $30.00M EDGAR
2018-07-20 Outlook Therapeutics, Inc. (ONSIW) Delisted Mixed — $0 EDGAR
2018-06-25 Outlook Therapeutics, Inc. (ONSIW) Delisted Mixed +132,982,149 $37.31M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.